首页> 外国专利> Aqueous powder and extended-release suspension comprising methylphenidate

Aqueous powder and extended-release suspension comprising methylphenidate

机译:包含哌醋甲酯的水性粉末和缓释悬浮液

摘要

An oral methylphenidate powder which is reconstitutable into a final oral aqueous sustained release formulation containing at least about 50% or at least about 80% by weight water based on the total weight of the suspension, is provided. The powder is a blend containing a combination of an uncoated methylphenidate - ion exchange resin complex, a barrier coated methylphenidate - ion exchange resin complex - matrix, and a water soluble buffering agent such that upon formed into an aqueous liquid formulation, the formulation has a pH in the range of about 3.5 to about 5, or about 4 Lo about 4.5. Following administration of a single dose of the oral aqueous methylphenidate suspension, a therapeutically effective amount of methylphenidate is reached in less than one hour and the composition provides a twelve-hour extended release profile.
机译:提供了可重新制成最终的口服含水缓释制剂的口服哌醋甲酯粉末,该制剂包含按悬浮液的总重量计至少约50重量%或至少约80重量%的水。该粉末是共混物,其包含未涂覆的哌醋甲酯-离子交换树脂复合物,阻隔涂覆的哌醋甲酯-离子交换树脂复合物-基质和水溶性缓冲剂的组合,这样在形成水性液体制剂时,该制剂就具有pH在约3.5至约5或约4至约4.5的范围内。在单剂量口服口服哌醋甲酯水悬浮液给药后,在不到一小时的时间内达到了治疗有效量的哌醋甲酯,该组合物提供了十二小时的缓释曲线。

著录项

  • 公开/公告号ES2721900T3

    专利类型

  • 公开/公告日2019-08-06

    原文格式PDF

  • 申请/专利权人 TRIS PHARMA INC.;

    申请/专利号ES20110705137T

  • 发明设计人 MEHTA KETAN;TU YU-HSING;PERUMAL ASHOK;

    申请日2011-02-15

  • 分类号A61K9/10;A61K9/50;A61K31/4458;

  • 国家 ES

  • 入库时间 2022-08-21 11:59:18

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号